In synucleinopathies, including Parkinson’s disease, NEGR1 has been indicated as a potential CSF biomarker in mass spectrometry studies, thus implicating relevance for diagnostic and therapeutic applications [94]. The gene discussed is NEGR1; the disease is Parkinson disease.